The Global Biologics Virus Filtration Market is driven by the rising prevalence of viral infections, such as HIV, which affects 37.7 million people globally, and the growing demand for biologic therapies such as monoclonal antibodies and vaccines. Stringent regulatory requirements and the need for safe blood products are boosting the adoption of virus filtration technologies. Additionally, the increasing use of gene and cell therapies further supports market growth, as these treatments require rigorous virus filtration during production to ensure safety and regulatory compliance.
